Market Place
Sourcing Support
Biogen reports promising results for higher dose of Spinraza
10 Oct 2024 //
PRESS RELEASE
Biogen Reports Positive Results For Higher Dose Nusinersen
04 Sep 2024 //
GLOBENEWSWIRE
Russia registers domestic generic of Spinraza
14 May 2024 //
THE PHARMA LETTER
Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA
06 Mar 2024 //
GLOBENEWSWIRE
New Data at Cure SMA Highlight Potential Benefit of SPINRAZA
30 Jun 2023 //
GLOBENEWSWIRE
Alcyone Receives FDA IDE Approval to Clinical Study ThecaFlex DRxTM of SPINRAZA
27 Jun 2023 //
PR NEWSWIRE
Royalty Pharma Acquires Ionis` Royalty In Spinraza, Pelacarsen For $1.1 Bln
10 Jan 2023 //
PR NEWSWIRE
Biogen Plans to start Phase 3b Study of High Dose Nusinersen
15 Sep 2021 //
GLOBENEWSWIRE
Biogen to test Spinraza in those who`ve had Roche`s Evrysdi
15 Sep 2021 //
FIERCEPHARMA
Biogen to Initiate PIIIb for Evaluating potential of Higher Dose of Nusinersen
15 Sep 2021 //
BIOSPACE
Biogen reports new data backing long-term benefit of Spinraza
11 Jun 2021 //
PHARMATIMES
Biogen reports new data backing long-term benefit of Spinraza
11 Jun 2021 //
PHARMATIMES
Biogen reports new data backing long-term benefit of Spinraza
11 Jun 2021 //
PHARMATIMES
Biogen reports new data backing long-term benefit of Spinraza
10 Jun 2021 //
PMLIVE
New Data on SPINRAZA (nusinersen) presented at Cure SMA 2021
10 Jun 2021 //
PRESS RELEASE
Pre symptomatic Infants with SMA Gets Motor Milestones After Evrysdi Treatment
10 Jun 2021 //
PRNEWSWIRE
Scholar Rock to Present Apitegromab Clinical Data from the TOPAZ Phase 2 Trial
07 Jun 2021 //
BUSINESSWIRE
NICE announces start of review of nusinersen Managed Access Agreement
29 Oct 2020 //
NICE.ORG
Roche touts 2-year Evrysdi data as oral SMA drug drives early interest
29 Sep 2020 //
FIERCEPHARMA
Roche says two-thirds of Evrysdi patients had got rival treatments
15 Sep 2020 //
REUTERS
Biogen to study Spinraza in patients who`ve received Zolgensma
21 Jul 2020 //
FIERCEPHARMA
New Results From Landmark NURTURE Study Show That Pre-Symptomatic SMA
10 Jun 2020 //
GLOBENEWSWIRE
Biogen’s blockbuster rare disease drug could be in trouble
01 May 2020 //
STATNEWS
Weeks after FDA delay,Roche, PTC unveil another batch of positive risdiplam data
29 Apr 2020 //
ENDPTS
Roche shares SMA data ahead of scrap with Biogen, Novartis
28 Apr 2020 //
FIERCE BIOTECH
Pharmac won`t fund drug Spinraza to help children with spinal muscular atrophy
24 Apr 2020 //
RANK
Biogen outlines setbacks, and potential gains, from COVID-19
22 Apr 2020 //
FIERCE PHARMA
Biogen CEO Vounatsos scores $18M-plus in 2019 pay
21 Apr 2020 //
FIERCE PHARMA
U.S. regulators delay decision on Roche SMA drug risdiplam to Aug. 24
08 Apr 2020 //
REUTERS
Biogen Announces First Patient Treated With Higher Dose of SPINRAZA®
02 Apr 2020 //
GLOBENEWSWIRE
Coronavirus delays Biogen`s Spinraza for some patients
20 Mar 2020 //
REUTERS
Novartis in talks with patients upset about lottery-like gene therapy giveaway
24 Dec 2019 //
REUTERS
Biogen`s Spinraza keeps churning even after Zolgensma launch
23 Oct 2019 //
FIERCE PHARMA
Biogen`s R&D head is out, following string of clinical setbacks
02 Oct 2019 //
BIOPHARMADIVE
Canadian star researcher brandishes Deep Genomics` first AI-discovered drug
25 Sep 2019 //
ENDPTS
Zolgensma didn`t cause an infant death, AveXis say as they spotlight data
19 Sep 2019 //
ENDPTS
While Novartis banishes Zolgensma scandal,Biogen goes on a Spinraza `offensive`
19 Sep 2019 //
ENDPTS
Don`t worry about Zolgensma, Biogen execs say. Spinraza has room to grow
23 Jul 2019 //
FIERCE PHARMA
FDA promises ‘elevated’ new drug approvals, but warns of potential pitfalls
10 Jul 2019 //
FIERCE PHARMA
Novartis struggling to win payer coverage for $2.1M gene therapy Zolgensma
04 Jul 2019 //
FIERCE PHARMA
Biogen`s Spinraza sharpens its case against Novartis gene therapy
01 Jul 2019 //
FIERCE PHARMA
Preclinical antisense biotech vaults on to Nasdaq with upsized IPO
20 Jun 2019 //
ENDPTS
Biogen trumpets safety data for Tecfidera follow-up
30 May 2019 //
PMLIVE
Ed Kaye is taking his fledgling biotech , looking for a new injection
24 May 2019 //
ENDPTS
Ionis launches first branding—30 years after it began
17 May 2019 //
FIERCE PHARMA
Spinraza managed access deal in England breaks deadlock for Biogen
16 May 2019 //
PMLIVE
Cost-effectiveness agency clears Biogen`s Spinraza for UK patients
16 May 2019 //
BIOPHARMADIVE
NICE recommends Sprinraza for 5q spinal muscular atrophy
15 May 2019 //
PHARMA TIMES
Roche, PTC post latest SMA data to rival Spinraza, Zolgensma
08 May 2019 //
FIERCE BIOTECH
Stanley Crooke on finally making sense out of antisense
07 May 2019 //
CEN
Ionis launches new corporate brand that reflects company`s industry innovation
06 May 2019 //
PR NEWSWIRE
Roche to present new data on Spinraza rival
29 Apr 2019 //
PMLIVE
Stung by aducanumab flop, Biogen execs confront their fears
25 Apr 2019 //
FIERCE PHARMA
To be cost-effective, Biogen should slash Spinraza price
04 Apr 2019 //
ENDPTS
Biogen investors have plenty to worry about, $5B buyback or no
27 Mar 2019 //
FIERCE PHARMA
Biogen beats estimates on multiple sclerosis drugs sales
29 Jan 2019 //
REUTERS
Orphan drugs from Biogen and Amicus win UK Prix Galien
17 Nov 2018 //
PM LIVE
An expensive new medication is finally available for her rare disease
10 Nov 2018 //
MARKET WATCH
Novartis says its top drug prospect is worth $4M-$5M for a once-and-done use
05 Nov 2018 //
ENDPTS
